in vitro ATAD2 inhibitor

Preclinical, oncology

from 1.8 million compound HTS and opt.

J. Med. Chem.


in vitro ATAD2 inhibitor - AstraZeneca

Context. AZ13824374 (AstraZeneca) is an in vitro ATAD2 inhibitor. Reviewer and nominator Julien Lefranc says, ‚Äúseveral ATAD2 probes have been published in the past (including GSK 8814, GSCK388, and…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: